

Assessment of the 90-day mortality risk score after video-assisted thoracoscopic lobectomy in the Italian VATS Group cohort

Andrea Imperatori,¹ Maria Cattoni,¹ Luca Bertolaccini,² Mario Nosotti,³ Lorenzo Rosso,³ Lucio Cagini,⁴ Jacopo Vannucci,⁴ Alessandro Brunelli,⁵ Roberto Crisci,⁶ Carlo Curcio,⁷ Nicola Rotolo,¹ on behalf of the Italian VATS Group

¹Center for Thoracic Surgery and Center for Minimally Invasive Surgery, Department of Medicine and Surgery, University of Insubria, Varese, Italy; ²Division of Thoracic Surgery, European Institute of Oncology (IEO) IRCCS, Milan, Italy; ³Thoracic Surgery and Lung Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ⁴Department of Thoracic Surgery, Medical School, University of Perugia, Italy; ⁵Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK; ⁶Thoracic Surgery Unit, University of L'Aquila, "G. Mazzini" Hospital, Teramo, Italy; ⁷Department of Thoracic Surgery, Monaldi Hospital, Naples, Italy

Correspondence: Andrea Imperatori, Center for Thoracic Surgery, Department of Medicine and Surgery, University of Insubria, Via Guicciardini 9, 21100 Varese, Italy.
Tel.: +390332393195.
Fax: +390332393630.
E-mail: andrea.imperatori@uninsubria.it

Key words: non-small cell lung cancer, VATS lobectomy, 90-day post-operative mortality, risk score, validation.

Contributions: AI, MC, NR, conceived and designed the study and wrote the first draft; AI, LB, MC, contributed to data analysis and interpretation. All authors collected data, revised and gave the final approval of the article version to be submitted.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: the Ethics Committee approved the study (protocol number: 0033034; ClinTrials.gov ID: NCT04799509).

Informed consent: all patients signed informed consent.

Funding: none.

Availability of data and materials: data and materials are available from the corresponding author upon request.

Received: 1 March 2023.

Accepted: 20 June 2023.

Early view: 28 July 2023.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2023

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2024; 94:2569

doi: 10.4081/monaldi.2023.2569

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

A five-class (A-E) aggregate risk score predicting 90-day mortality after video-assisted thoracoscopic lobectomy for lung cancer, including as independent factors male sex (3 points), carbon monoxide lung diffusion capacity $\leq 60\%$ (1 point), and operative time ≥ 150 minutes (1 point), has been recently published. This study aims to assess the effectiveness and reliability of this risk model in a large, independent cohort of patients to confirm its generalizability. From the Italian VATS Group database, we selected 2209 patients [60% males; median age 69 years (interquartile range: 63-74)] who underwent video-assisted thoracoscopic lobectomy for non-small cell lung cancer. We calculated the aggregate risk score and the corresponding class of 90-day mortality risk for each patient. The correlation between risk classes and mortality rates was tested by Spearman's r -test. Model calibration was evaluated by the Hosmer-Lemeshow goodness-of-fit test. Class A-E 90-day mortality rates were 0.33%, 0.51%, 1.39%, 1.31%, and 2.56%, respectively. A strong uphill correlation was identified between risk classes and 90-day mortality ($r=0.90$; $p=0.037$), showing a positive correlation between increased mortality rate and classes A to E. Hosmer-Lemeshow Chi-squared value was 67.47 ($p<0.001$), with overall, class D and E significantly lower 90-day mortality in our cohort than in the original one [1.04% versus 2.5% ($p=0.018$), 1.31% versus 5.65% ($p=0.005$) and 2.56% versus 18.75% ($p=0.007$), respectively]. Despite our data showing a positive correlation between 90-day mortality and risk classes from A to E with modest discriminatory performance, the poor calibration suggests the need for model recalibration using local data to better manage and counsel lung cancer patients eligible for video-assisted thoracoscopic lobectomy.

Introduction

Lung lobectomy and lymph node dissection are the "gold standard" treatments for early-stage non-small cell lung cancer (NSCLC) [1]. However, the 90-day mortality rate after this surgical procedure still ranges between 0.3% and 4.6%, despite the fact that the introduction of the video-assisted thoracoscopic surgery (VATS) approach has significantly enhanced postoperative recovery, reduced morbidity, length of stay, and, in some studies, mortality [2-12]. Thus, being aware of the individual 90-day mortality risk after VATS lobectomy is fundamental for NSCLC patients' management

and preoperative counseling, mainly when patients have borderline clinical conditions for surgery.

In order to address this issue, Brunelli *et al.* have published a five-class aggregate risk score predicting 90-day mortality after VATS lobectomy for NSCLC, including as independent factors male sex, carbon monoxide lung diffusion capacity (DLCO), and operative time [12]. This model has been found promising in a single-center series of patients, but a solid test in a more extended independent cohort is recommended to confirm its generalizability before clinical application.

This study aims to assess the reliability and validity of this aggregate risk score predicting 90-day mortality after VATS lobectomy for NSCLC in the independent multicenter cohort of the Italian VATS Group registry.

Materials and Methods

From the Italian VATS Group registry (a database containing prospectively collected data on VATS anatomical lung resection performed in 58 certified thoracic surgery centers from January 1, 2014), we selected patients who underwent VATS lobectomy and lymphadenectomy for NSCLC from January 1, 2014, to November 27, 2018. After a quality inspection of the data, the VATS Group database was awarded by the European Society of Thoracic Surgeons in 2017. Patients with incomplete data for risk score calculation, tumor size ≥ 5 cm, follow-up ≤ 3 months and those who underwent neoadjuvant treatment and/or extended resection were excluded from the study, according to the original study [12]. The Ethics Committee approved the study (protocol number: 0033034; ClinTrials.gov ID: NCT04799509), and all patients signed informed consent. This research is being reported in line with the STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery [13].

Patients' records included: age, gender, comorbidity, Eastern Cooperative Oncology Group performance status, forced expiratory volume in 1 second (FEV₁), DLCO, tumor clinical 7th edition tumor-node-metastasis (TNM) stage, surgical approach, surgical procedure, operating time, tumor histology, size, and pathological 7th edition TNM stage, postoperative complications, postoperative length of stay, follow-up at 30 and 90 days after surgery.

For each patient, we calculated the corresponding risk class of postoperative 90-day mortality [A (0 points); B (1-2 points); C (3 points); D (4 points); E (5 points)] summing the score related to the following variables included in Brunelli *et al.*'s aggregate risk score [12]: i) male sex = 3 points; ii) DLCO $\leq 60\%$ = 1 point; iii) operating time ≥ 150 minutes = 1 point.

The 90-day mortality rate was calculated for each risk class. To assess the effectiveness and reliability of this risk model in our cohort of patients, the correlation between risk classes and 90-day mortality rates, and overall model calibration were assessed in our multinstitutional cohort. Then, our results were compared to those of Brunelli *et al.*

Statistical analysis

Continuous data were reported as medians with an interquartile range (IQR). Categorical and count data were presented as frequencies and percentages and compared by the Chi-square test (Fisher's exact test if there was any expected frequency ≤ 5). The correlation between risk classes and the mortality rate was tested by Spearman's r -test. Model calibration was evaluated by the Hosmer-Lemeshow goodness-of-fit test. Significance was defined as a $p \leq 0.05$. Statistical

analysis was performed using SPSS 24.0 software (IBM, Armonk, NY, USA) and R software (version 3.6.1, Action of the Toes) with standard, *rcmdr*, and *irr* packages (R Core Team, 2019. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>).

Results

In the study period (from January 1, 2014, to November 27, 2018), the Italian VATS Group database included 6019 patients who underwent VATS lobectomy for NSCLC. According to the study inclusion/exclusion criteria, we excluded 3810 patients, leaving 2209 records for statistical analysis (Figure 1). Patients' demographic and clinicopathological characteristics are listed in Table 1. All patients underwent a lobectomy. Lymph node radical dissection was performed in 1503 (69%) patients, and lymph node sampling was performed in 691 (31%), but in 15 cases, this data was not available. The surgical approach was tri-portal VATS in 1458 (66%) cases, bi-portal VATS in 397 (18%), and uniportal VATS in 228 (10%). In 126 (6%) patients, lobectomy was approached by four ports. Conversion to open thoracotomy occurred in 190 (8.6%) cases. The median operating time was 180 (IQR: 140-220) minutes. Adjuvant treatment was performed in 239 (11%) patients: 201 chemotherapy, 16 radiotherapy, and 22 both chemo and radiotherapy.

The overall postoperative morbidity rate was 28% (610/2209 patients). In detail, the most frequent complications were: 176 (8.0%) cardiovascular; 176 (8.0%) prolonged air leak (≥ 7 days); 159 (7.2%) respiratory; and 41 (1.9%) surgical hemo/chylothorax. The median postoperative length of stay was 5 days (IQR: 4-7). 11 patients died within 30 days after surgery: four for acute respiratory failure, two for cardiovascular disease, one for hemorrhage, one for multiple organ failure, one for abdominal disease, and one for other cancer hemorrhages. In one case, the cause of death was not specified. Moreover, 12 patients died between the 31st and the 90th postoperative day: six for cardiovascular disease, one for acute respiratory failure, one for sepsis, one for trauma, and one for alimentary intoxication. In two cases, the cause of death was not reported. Overall postoperative mortality rates at 30 and 90 days were 0.50% (11/2209) and 1.04% (23/2209), respectively.

After calculating the aggregate risk score of postoperative 90-day mortality for each patient in our cohort, 301 (14%) patients were fitted in class A, 593 (27%) in class B, 359 (16%) in class C, 839 (38%) in class D and 117 (5%) in class E. The rates of 90-day mortality per class in our cohort and Brunelli *et al.*'s are reported in Table 2.

The Spearman's ρ -test showed a strong uphill correlation between risk classes and 90-day mortality rate in our cohort ($\rho=0.90$; $p=0.037$) as in the original one ($\rho=1.00$; $p \leq 0.001$), showing an increased mortality risk from class A to E, as shown in Figure 2. However, in our cohort, class C and class D had similar rates of 90-day mortality after surgery (1.39% and 1.31%, respectively).

To better understand the reason for a similar 90-day mortality rate in classes C and D, we analyzed the impact of each risk factor on 90-day mortality in our cohort and the distribution of these risk factors in class C and D. Regarding the relationship between 90-day mortality and every risk factor, the 90-day mortality rate was 0.47% (4/894) among females *versus* 1.44% (19/1,315) among males ($p=0.034$); 0.82% (16/1941) among patients with DLCO $\geq 60\%$ *versus* 2.61% (7/268) among those with DLCO $\leq 60\%$ ($p=0.008$); 1.2% (9/749) when surgery lasted ≤ 150 minutes *versus* 0.96% (14/1460) when it lasted ≥ 150 minutes ($p=0.60$). In class C, all patients were

male with DLCO \geq 60% and surgery lasting \leq 150 minutes. In class D, all patients were male, in 5.8% (49/839) cases, DLCO was \leq 60%, and in 94% (790/839), surgery lasted \geq 150 minutes.

Comparing our overall and per-class postoperative 90-day mortality rates to those of Brunelli *et al.*, we observed a significantly lower overall 90-day mortality rate in our cohort than in Brunelli *et al.*'s one (1.04% versus 2.5%; $p=0.018$). The same difference was detected for classes D and E, whose 90-day mortality rates were lower in our population than in the original one (Table 2) ($p=0.005$ and $p=0.007$, respectively). No differences were observed comparing classes A, B, and C 90-day mortality rates between the two cohorts (Table 2) ($p=1.00$, $p=1.00$, and $p=1.00$, respectively). The Hosmer-Lemeshow Chi-squared value in our cohort was 67.47 ($p\leq 0.001$).

Discussion

In the era of VATS affirmation as the preferred approach even for lobectomy and lymph node dissection for NSCLC, the estimation of individual mortality risk after this surgical procedure is crucial to deciding the most appropriate treatment strategy for each patient with NSCLC. Numerous data have been reported regarding in-hospital/30-day mortality after VATS lobectomy in lung cancer patients, and several postoperative 30-day mortality risk scores have been proposed, comprising major anatomical lung resections performed either by thoracotomy or by VATS [14-16]. However, according to recent studies, mortality between the 30th and 90th postoperative days is still relevant, suggesting surgery effects last probably longer than 30 days after the surgical procedure and empathizing with the need to move clinician attention to 90-day mortality and factors associated with it [2-11].

The study by Brunelli *et al.* is the first one analyzing 90-day mortality in the specific cohort of VATS lobectomy for NSCLC. They propose five classes (class A-E) aggregate risk score of postoperative 90-day mortality [12]. Our study tested Brunelli *et al.*'s




Figure 1. Patients' enrollment in the current study. DLCO, carbon monoxide lung diffusion capacity; NSCLC, non-small cell lung cancer; pts, patients; VATS, video-assisted thoracic surgery.

model in the large, multicenter, independent cohort of the Italian VATS Group registry and showed that the proposed aggregate risk score is predictive of 90-day mortality after VATS lobectomy, with the mortality rate increasing significantly from class A to E. Moreover, the risk class calculation for each patient appeared to be simple, requiring only the sum of the scores related to three easily identifiable parameters: gender, DLCO, and operative duration. These findings apparently suggest the possible introduction of Brunelli *et al.*'s aggregate risk score in our daily clinical practice as an additional tool in the management of NSCLC patients.

However, our results require some observations. Overall and for higher-risk classes (classes D and E), 90-day mortality risk rates are significantly lower in our cohort than in the original one. This is probably due to the worse respiratory function of Brunelli *et al.*'s population (mean FEV₁=88.0 \pm 21.1%; mean DLCO=71.8 \pm 16.4%) [12]. In fact, in their cohort, half of the postoperative deaths are due to respiratory complications. However, both overall 90-day mortality values are consistent with literature reports that assess 90-day

Table 1. Demographic and clinical characteristics of 2209 patients from the Italian VATS Group registry who underwent video-assisted thoracoscopic lobectomy for non-small cell lung cancer.

Patients' characteristics	
Age, median (IQR) years	69 (63-74)
Male, n (%)	1315 (60)
FEV ₁ , median (IQR), n (%)	96 (82-109)
DLCO, median (IQR), n (%)	82 (68-94)
Significant co-morbidity	
Myocardial infarction, n (%)	212 (10)
Congestive heart failure, n (%)	68 (3)
Cerebrovascular disease, n (%)	141 (6)
Diabetes, n (%)	275 (12)
COPD	383 (17)
ECOG	
	n (%)
0	1708 (77)
1	432 (20)
2-3	69 (3)
Side right	1355 (61)
Side upper	1285 (58)
Histology	
	n (%)
Adenocarcinoma	1605 (73)
Squamous cell carcinoma	331 (15)
Adenosquamous carcinoma	24 (1)
Large cell carcinoma	14 (1)
Large cell neuroendocrine carcinoma	28 (1)
Carcinoid	183 (8)
Others	24 (1)
pStage	
	n (%)
I	1782 (81)
II	249 (11)
III	178 (8)

COPD, chronic obstructive pulmonary disease; DLCO, carbon monoxide lung diffusion capacity; ECOG, Eastern Cooperative Oncology Group performance status; FEV₁, forced expiratory volume in 1 second; IQR, interquartile range; pStage, pathological stage (according to 7th edition TNM stage).

mortality after lobectomy up to 4.6% [2-8]. Moreover, in our population, no difference in terms of the mortality rate was observed between class C and class D, probably due to the overall better condition of our patients and the absence of an impact of surgical duration, defined by the 150-minute cut-off value.

The discrepancies in patients' clinical status explain the model's poor calibration revealed by the Hosmer-Lemeshow goodness-of-fit test and suggest the need for model recalibration using local data to better manage and counsel NSCLC patients eligible for VATS lobectomy.

Another essential observation concerns the aggregate risk score itself and specifically one of its three variables: duration of surgery. Prolonged surgical time and anesthesia have been largely proven to negatively influence the postoperative course [12]. However, the cut-off value of 150 minutes for the operative time may not be generalizable to all institutions because it varies with surgeon experience, individual surgical volume, and case complexity. Thus, before calculating the risk score, the operative time cut-off value should be recalibrated locally to better fit each institution setting. Moreover, surgical duration is not known preoperatively, suggesting that the surgical risk can be discussed during the multidisciplinary meeting and presented to the patient only as a range of estimates depending on whether the surgical time will be longer or shorter than the referral one, taking into consideration the possibility of changing the sur-




Figure 2. The correlation between risk classes (from class A to E) and 90-day mortality rate after video-assisted thoracic lobectomy for non-small cell lung cancer in the Italian VATS Group cohort. VATS, video-assisted thoracic surgery.

gical choices and approaches mainly in male patients with a $DLCO \leq 60\%$ (class D).

Managing patients who are candidates for VATS lobectomy for NSCLC, Brunelli *et al.*'s model may be used several times: during multidisciplinary boards in choosing the most adequate treatment strategy; during surgery, to evaluate conversion of the surgical procedure from VATS to thoracotomy; and after surgery, to better modulate high-risk patients' cure and monitoring before and after discharge.

More in detail, after estimating the predicted mortality rates per risk class in its own institution, patients' 90-day mortality risk should be calculated preoperatively using surgical duration as a reference to its own median surgical time for VATS lobectomy and lymphadenectomy. High-risk patients should be discussed and possibly proposed for sublobar resection, stereotactic radiotherapy, or radiofrequency. For surgical candidates, surgeons should evaluate the conversion of the surgical procedure from VATS to thoracotomy whenever surgery delays over the regular timetable, upgrading the patient to a higher risk class. Finally, since the leading causes of death were respiratory failure within 30 days after surgery and cardiovascular disease during the following 60 days, high-risk patients may benefit from a more intensive postoperative respiratory physiotherapy program during their early postoperative course to reduce respiratory complications and form a cardiological check before discharge to assess heart function after surgery and to eventually introduce appropriate cardiac therapy, preventing respiratory and cardiac deaths, respectively.

This study has some limitations. The first is its retrospective nature. A prospective validation study may overcome the issue; however, the Italian VATS Group registry comprises prospectively collected data, granting a better reconstruction of patients' clinical history and limiting missing information. The quality of these data was awarded by the European Society of Thoracic Surgeons in 2017 after a proper inspection. A second limitation is that the number of events is low, suggesting that a few events can drive results in different ways. Though statistical analysis and result evaluation have been performed aware of this limitation, we also underline that the use of the Spearman rank correlation coefficient recognizes some limitations. Values of both variables are assumed to describe a linear relationship rather than a non-linear one; a sizeable computational time is required when the number of pairs of values of two variables exceeds 30 and assigning ranks to each numerical value is very time-consuming. This method cannot be applied to measure the association between two variables whose distribution is given as a grouped frequency distribution.

Finally, we could not compare Brunelli *et al.*'s model to the available scores for mortality prediction after lung resection [the Thoracoscore, the EuroLung2, and the Society of Thoracic Surgeons (STS) score] because these models have been developed with the specific aim of predicting 30-day and not 90-day mortality after sur-

Table 2. 90-day mortality rates by risk aggregate score classes: the Italian VATS Group cohort and Brunelli *et al.*'s cohort.

Class	Italian VATS Group cohort		Brunelli <i>et al.</i> 's cohort [12]			
	n (%)	Death, n	90-day mortality, %	n (%)	Death, n	90-day mortality, %
A	301 (14)	1	0.33	155 (21)	0	0.00
B	593 (27)	3	0.51	262 (36)	1	0.38
C	359 (16)	5	1.39	107 (15)	1	0.93
D	839 (38)	11	1.31	177 (24)	10	5.65
E	117 (5)	3	2.56	32 (5)	6	18.75

gery [16-18]. Furthermore, Brunelli *et al.*'s score exclusively focuses on lung lobectomy performed by VATS, while the Thoracscore, EuroLung2, and STS score refer to various kinds of lung resections (from wedge resection to pneumonectomy) mostly approached by thoracotomy [16-18].

Conclusions

To conclude, when tested in the Italian VATS Group dataset, the aggregate risk score of 90-day mortality after VATS lobectomy, proposed by Brunelli *et al.*, showed a positive correlation with mortality rate from class A to class E, with modest discriminatory performance but poor calibration. This suggests that the applicability of this risk model to manage and counsel NSCLC patients eligible for VATS lobectomy is easy and feasible; however, to obtain better performance, operating time cut-off values may be revised and adjusted according to local data.

References

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small cell lung cancer. Version 3.2022. Available from: www.NCCN.org. Accessed on: 18/03/2022.
2. Al-Ameri M, Bergman P, Franco-Cereceda A, Sartipy U. Video-assisted thoracoscopic versus open thoracotomy lobectomy: a Swedish nationwide cohort study. *J Thorac Dis* 2018;10:3499-506.
3. Pezzi CM, Mallin K, Mendez AS, et al. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. *J Thorac Cardiovasc Surg* 2014;148:2269-77.
4. McMillan RR, Berger A, Sima CS, et al. Thirty-day mortality underestimates the risk of early death after major resections for thoracic malignancies. *Ann Thorac Surg* 2014;98:1769-74.
5. Powell HA, Tata LJ, Baldwin DR, et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. *Thorax* 2013;68:826-34.
6. Hu Y, McMurry TL, Wells KM, et al. Postoperative mortality is an inadequate quality indicator for lung cancer resection. *Ann Thorac Surg* 2014;97:973-9.
7. Green A, Hauge J, Iachina M, Jakobsen E. The mortality after surgery in primary lung cancer: results from the Danish Lung Cancer Registry. *Eur J Cardiothorac Surg* 2016;49:589-94.
8. Bryant AS, Rudemiller K, Cerfolio RJ. The 30- versus 90-day operative mortality after pulmonary resection. *Ann Thorac Surg* 2010;89:1717-22.
9. Stephens N, Rice D, Correa A, et al. Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical Stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases. *Eur J Cardiothorac Surg* 2014;46:607-13.
10. Falcoz PE, Puyraveau M, Thomas PA, et al. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. *Eur J Cardiothorac Surg* 2016;49:602-9.
11. Cao C, Manganas C, Ang SC, et al. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. *Interact Cardiovasc Thorac Surg* 2013;16:244-9.
12. Brunelli A, Dinesh P, Woodcock-Shaw J, et al. Ninety-day mortality after video-assisted thoracoscopic lobectomy: incidence and risk factors. *Ann Thorac Surg* 2017;104:1020-6.
13. Agha R, Abdall-Razak A, Crossley E, et al. STROCSS 2019 Guideline: strengthening the reporting of cohort studies in surgery. *Int J Surg* 2019;72:156-65.
14. Ganai S, Ferguson MK. Can we predict morbidity and mortality before an operation?. *Thorac Surg Clin* 2013;23:287-99.
15. Berrisford R, Brunelli A, Rocco G, et al. The European Thoracic Surgery Database project: modelling the risk of in-hospital death following lung resection. *Eur J Cardiothorac Surg* 2005;28:306-11.
16. Brunelli A, Salati M, Rocco G, et al. European risk models for morbidity (EuroLung1) and mortality (EuroLung2) to predict outcome following anatomic lung resections: an analysis from the European Society of Thoracic Surgeons database. *Eur J Cardiothorac Surg* 2017;51:490-7.
17. Kozower BD, Sheng S, O'Brien SM, et al. STS database risk models: predictors of mortality and major morbidity for lung cancer resection. *Ann Thorac Surg* 2010;90:875-81.
18. Falcoz PE, Conti M, Brouchet L, et al. The Thoracic Surgery Scoring System (Thoracscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. *J Thorac Cardiovasc Surg* 2007;133:325-32.